Phase 3 Retatrutide trials currently underway will address these gaps with larger, longer studies before FDA submission
GLP-1 receptor agonists have gained attention primarily for weight loss, yet mounting clinical evidence indicates they may also address systemic inflammationa silent driver of cardiovascular disease, type 2 diabetes, and metabolic dysfunction
What has been slower to emerge is a framework that recognizes these not as independent problems but as coordinated consequences of a single underlying disruption: the withdrawal of hormonal signals that had, for decades, been quietly governing cellular energy regulation, inflammatory tone, and tissue maintenance throughout the body
Proper medical oversight during administration minimizes these risks
6.1 Insulin therapy Absolute insulin deficiency is the main characteristic of PDM that makes insulin replacement the foundation of its treatment ( 6.1.1 Principles of insulin therapy The most flexible option from a physiological point of view is the basal-bolus regimen, which comprises basal insulins of long-acting formulations such as glargine and degludec, and rapid-acting insulins at meal-time
Smart storage habits at home The best storage spot in your fridge is not the door